Loading patent…
AssigneesCrucell Holland B.V., Aeras Global TB Vaccine Foundation
InventorsMenzo J. E. Havenga, Ronald Vogels, Jerald Sadoff, David Hone, Yasir A. W. Skeiky, Katarina Radosevic
Estimating the term…
The invention relates to vaccines comprising recombinant vectors, such as recombinant adenoviruses. The vectors comprise heterologous nucleic acids encoding for at least two antigens from one or more tuberculosis-causing bacilli. The invention also relates to the use of specific protease recognition sites linking antigens through which the encoded antigens are separated upon cleavage. After cleavage, the antigens contribute to the immune response in a separate manner. The recombinant vectors may comprise a nucleic acid encoding the protease cleaving the linkers and separating the antigens. The invention furthermore relates to the use of genetic adjuvants encoded by the recombinant vectors, wherein such genetic adjuvants may also be cleaved through the presence of the cleavable linkers and the specific protease.
A recombinant replication-defective adenovirus comprising a nucleic acid sequence encoding antigens from the Ag85A, the Ag85B and the TB10.4 open reading frames of Mycobacterium tuberculosis, wherein the nucleic acid sequence comprises, in the 5′ to 3′ direction, an expression control sequence, the Ag85A coding sequence, the Ag85B coding sequence, and the TB10.4 coding sequence.
Dependencies are inferred from the claim text.